数千万元！追光生物完成天使+轮融资，加速光电镊等技术产业化进程

Core Viewpoint - The recent funding round for Chasing Light Biotechnology aims to enhance its optoelectronic microfluidic product line, develop bio-MEMS applications, and expand its marketing network, thereby promoting the localization of high-end life science instruments [2]. Group 1: Company Overview - Chasing Light Biotechnology was founded in 2023 by professors from Beijing Institute of Technology, Southern University of Science and Technology, and Jinan University, along with several overseas PhDs [2]. - The company focuses on empowering life sciences through technology, aiding biomedicine and gene therapy, and accelerating the transformation of scientific research achievements [2]. - Chasing Light develops high-end life science instrument platforms to address critical technological challenges in the field [2][11]. Group 2: Product Offerings - The company offers products including an optoelectronic microfluidic platform, digital microfluidic platform, structured light projection devices, and microscope accessories [2]. - The OptoBot® 1000 single-cell optoelectronic microfluidic system utilizes optical tweezers and fully automated microfluidic chip principles to reduce experimental cycles from 2-3 months to 1-2 weeks while saving labor and consumable costs [3]. - The DropletBot® digital microfluidic platform is based on electrowetting principles, allowing precise control of discrete droplets for applications in biology and chemistry [6]. - The OptoNeuroBot® structured light projector employs digital micromirror device technology for precise spatial and temporal light control, compatible with mainstream microscopes [7]. Group 3: Team Expertise - The core team includes professionals with extensive experience in medical device development, project management, and financial management across various industries [11][12][13][15]. - The team combines expertise from academia and industry to continuously develop new instrument platforms in the life sciences field [11].